Radiation therapy of small cell lung cancer with 177Lu-DOTA- Tyr3-octreotate in an animal model

Journal of Nuclear Medicine

Volumn 45, Issue 9, 2004, Pages 1542-1548

  Schmitt, Anneli ^a   Bernhardt, Peter ^a   Nilsson, Ola ^a   Ahlman, Håkan ^a   Kölby, Lars ^a   Maecke, Helmut R ^b   Forssell Aronsson, Eva ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

177Lu DOTA Tyr3 octreotate; Nude mice; Radionuclide therapy; Small cell lung cancer

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE N,N',N'',N''' TETRAACETIC ACID TYR 3 OCTREOTATE LU 177; RADIOISOTOPE; UNCLASSIFIED DRUG; (177LUTETIUM DOTA(O)TYR3)OCTREOTATE; (177LUTETIUM-DOTA(O)TYR3)OCTREOTATE; ORGANOMETALLIC COMPOUND; RADIOPHARMACEUTICAL AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER RADIOTHERAPY; CONTROLLED STUDY; DRUG ABSORPTION; DRUG MECHANISM; DRUG TISSUE LEVEL; LUNG SMALL CELL CANCER; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR REGRESSION; TUMOR VOLUME; XENOGRAFT; ANIMAL; ANTIBODY SPECIFICITY; BAGG ALBINO MOUSE; COMPARATIVE STUDY; DISEASE MODEL; INTRAVENOUS DRUG ADMINISTRATION; LUNG TUMOR; METABOLIC CLEARANCE RATE; METABOLISM; NUDE MOUSE; SMALL CELL CARCINOMA; TISSUE DISTRIBUTION; TREATMENT OUTCOME;

ANIMALS; CARCINOMA, SMALL CELL; DISEASE MODELS, ANIMAL; INJECTIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; METABOLIC CLEARANCE RATE; MICE; MICE, INBRED BALB C; MICE, NUDE; ORGAN SPECIFICITY; ORGANOMETALLIC COMPOUNDS; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION; TREATMENT OUTCOME;

EID: 6944223855     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Benali N, Ferjoux G, Puente E, Buscail L, Susini C. Somatostatin receptors. Digestion. 2000;62(suppl 1):27-32.
2. Reubi JC, Waser B, Schaer JC, Laissue JA. Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med. 2001;28:836-846.
3. Forssell-Aronsson E, Fjalling M, Nilsson O, Tisell LE, Wangberg B, Ahlman H. Indium-111 activity concentration in tissue samples after intravenous injection of indium-111-DTPA-D-Phe-1-octreotide. J Nucl Med. 1995;36:7-12.
4. 3-octreotide: clinical dosimetry and use for internal radiotherapy of metastatic paraganglioma and carcinoid tumors. Nucl Med Biol. 2000;27:809-813.
5. Kwekkeboom D, Krenning EP, de Jong M. Peptide receptor imaging and therapy. J Nucl Med. 2000;41:1704-1713.
6. 111In-pentetreotide: initial observations and future directions. Cancer J Sci Am. 1998;4:94-102.
7. de Jong M, Valkema R, Jamar F, et al. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings. Semin Nucl Med. 2002;32:133-140.
8. 3-octreotide (DOTATOC): a pilot study in human gliomas. Clin Cancer Res. 1999;5:1025-1033.
9. Otte A, Herrmann R, Heppeler A, et al. Yttrium-90-DOTATOC: first clinical results. Eur J Nucl Med. 1999;26:1439-1447.
10. 90Y-DOTATOC. J Nucl Med. 2002;43:610-616.
11. 3-octreotide. Eur J Nucl Med. 2001;28:426-434.
12. 90Y-labelled peptidic vector DOTATOC to control gliomas of WHO grades II and III: an extended pilot study. Eur J Nucl Med. 2002;29:486-493.
13. Virgolini I, Britton K, Buscombe J, Moncayo R, Paganelli G, Riva P. In- and Y-DOTA-lanreotide: results and implications of the MAURITIUS trial. Semin Nucl Med. 2002;32:148-155.
14. 3]octreotate. Eur J Nucl Med. 2003;30:417-422.
15. Simon GR, Wagner H. Small cell lung cancer. Chest. 2003;123:259S-271S.
16. Reubi JC, Waser B, Sheppard M, Macaulay V. Somatostatin receptors are present in small-cell but not in non-small-cell primary lung carcinomas: relationship to EGF-receptors. Int J Cancer. 1990;45:269-274.
17. 111In-DTPA octreotide scintigraphy. Eur J Cancer. 1995;31A:184-188.
18. Hochstenbag MM, Heidendal GA, Wouters EF, ten Velde GP. In-111 octreotide imaging in staging of small cell lung cancer. Clin Nucl Med. 1997;22:811-816.
19. Reisinger I, Bohuslavitzki KH, Brenner W, et al. Somatostatin receptor scintigraphy in small-cell lung cancer: results of a multicenter study. J Nucl Med. 1998;39:224-227.
20. Taylor JE, Theveniau MA, Bashirzadeh R, et al. Detection of somatostatin receptor subtype 2 (SSTR2) in established tumors and tumor cell lines: evidence for SSTR2 heterogeneity. Peptides. 1994;15:1229-1236.
21. 3]octreotate in male nude mice with human small cell lung cancer. Cancer Biother Radiopharm. 2003;18:597-603.
22. Bernhardt P, Benjegard SA, Kolby L, et al. Dosimetric comparison of radionuclides for therapy of somatostatin receptor-expressing tumors. Int J Radiat Oncol Biol Phys. 2001;51:514-524.
23. 3-octreotate in tumor-bearing rats. Nucl Med Biol. 2001;28:327-334.
24. 161Tb-DTPA-octreotide, a somatostatin analogue with potential for intraoperative scanning and radiotherapy. Eur J Nucl Med. 1995;22:608-616.
25. 3]octreotate for somatostatin receptor-targeted radionuclide therapy. Int J Cancer. 2001;92:628-633.
26. 3-octreotate in a rat model. Int J Cancer. 2001;94:873-877.
27. Zamora PO, Bender H, Gulhke S, et al. Pre-clinical experience with Re-188-RC-160, a radiolabeled somatostatin analog for use in peptide-targeted radiotherapy. Anticancer Res. 1997;17:1803-1808.
28. 3-octreotate in a somatostatin receptor-positive, tumor-bearing rat model. Clin Cancer Res. 1999;5:3608-3616.
29. 3-octreotide as a potential agent for positron emission tomography imaging and receptor mediated internal radiotherapy of somatostatin receptor positive tumors. Nucl Med Biol. 2002;29:147-157.
30. 1-octreotide. Nucl Med Biol. 2000;27:183-188.
31. Li W, Ma D, Higginbotham C, et al. Development of an in vitro model for assessing the in vivo stability of lanthanide chelates. Nucl Med Biol. 2001;28:145-154.
32. Reubi JC, Schar JC, Waser B, et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphy and radiotherapeutic use. Eur J Nucl Med. 2000;27:273-282.
33. Loevinger R. MIRD Primer for Absorbed Dose Calculations. New York, NY: Society of Nuclear Medicine; 1988.
34. Sowby FD, ed. ICRP Publication 36: Radionuclide Transformations. Oxford, U.K.: Pergamon Press; 1983:756.
35. Wyckoff HO. ICRU Publication 37: Stopping Powers for Electrons and Positrons. Bethesda, MD: International Commission on Radiation Units and Measurements; 1984:206.
36. 1-octreotide in tumor-bearing nude mice: influence of amount injected and route of administration. Nucl Med Biol. 2003;30:253-260.
37. 3]octreotide is dependent on the peptide amount. Eur J Nucl Med. 1999;26:693-698.
38. Wängberg B, Nilsson O, Johanson V, et al. Somatostatin receptors in the diagnosis and therapy of neuroendocrine tumors. Oncologist. 1997;2:50-58.